The efficacy of fleroxacin versus that of vancomycin was assessed by using the rabbit model of methicillinresistant Staphylococcus aureus endocarditis. Animals were treated with fleroxacin (30 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg every 6 h) for 4 days. These antimicrobial agents were equally effective in clearing bacteremia, reducing bacterial counts in vegetations and tissues, and curing endocarditis. However, resistance to fleroxacin at fivefold the MIC arose in the test strain of S. aureus in 8% of animals that received the drug. We conclude that fleroxacin is as efficacious as vancomycin in this model of a serious systemic S. aureus infection, but modest resistance to fleroxacin may develop during therapy.
The fluoroquinolones are potent antimicrobial agents having excellent activity against a broad range of bacteria, including methicillin-resistant Staphylococcus auireus (15) . Fleroxacin, a new trifluorinated quinolone, has significant activity against both methicillin-susceptible and -resistant strains of S. aureus in vitro (2) , and it has favorable pharmacokinetics, suggesting that once-or twice-daily dosing will be possible in humans (14) .
Recently, reports of vancomycin resistance in previously susceptible gram-positive bacteria have appeared (8, 10) . Because of this occurrence, it is sensible to examine other therapeutic options for infections caused by organisms for which vancomycin is the mainstay of therapy. Therefore, we examined the efficacy of fleroxacin versus that of vancomycin by using the rabbit model of methicillin-resistant S. aureus endocarditis. This model affords a severe test of antimicrobial efficacy in a serious systemic infection.
MATERIALS AND METHODS
Organism. The methicillin-resistant strain of S. aureus used (MRSA 494) was a bloodstream isolate from a patient with endocarditis.
In vitro studies. The MICs and MBCs of methicillin, vancomycin, and fieroxacin for MRSA 494 were determined by a microdilution method using cation-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) (4) . The frequency at which MRSA 494 developed spontaneous mutational resistance to 2-, 5-, and 10-fold its fleroxacin MIC was determined by exposing exponential-growth-phase organisms (-101o CFU) to the appropriate concentration of fleroxacin incorporated into Mueller-Hinton agar (Difco). Colonies were counted 48 h later.
Serum inhibitory and bactericidal titers (SITs and SBTs)
were determined by a microdilution method modified by using cation-supplemented Mueller-Hinton broth as the diluent, because the protein binding of fleroxacin (30%) or vancomycin (50%) is not significant (12) . Animal studies. All studies were done using male New Zealand White rabbits (2 to 3 kg). Single-and multiple-dose pharmacokinetic studies with fleroxacin were performed with hpalthy animals to determine a dose and dosing interval which produced levels in serum approximating those achievable in humans. Five animals received single intravenous (i.v.) bolus doses of 35 mg/kg of body weight, followed by frequent collection of serum samples for the next 12 h for the determination of fleroxacin content. For multiple-dose studies, five animals received 17.5 mg/kg i.v. every 12 h, for a total of 9 doses. Following dose 9, serum was collected on a schedule similar to that for single-dose studies and was assayed for fleroxacin content. Serum fleroxacin concentration-time curves were plotted, and the elimination half-life was estimated from the slope of the plotted line. Other pharmacokinetic parameters (plasma clearance and steadystate volume of distribution) were determined by modelindependent methods (5). Similar studies have previously been performed with vancomycin (1).
Left-sided endocarditis was established as described previously by using an i.v. bacterial inoculum of 106 CFU (6) . After 18 h, all animals had 1 ml of blood withdrawn for culture. Serial dilution and plating techniques were used to determine CFU per milliliter of blood. Inclusion in the study required that this blood culture be positive and that the catheter be positioned properly across the aortic valve at autopsy.
Rabbits were randomized to receive 4 days of fleroxacin (30 mg/kg i.v. every 8 h), vancomycin (17.5 mg/kg i.v. every 6 h), or no treatment (controls). The dose administered was adjusted for weight on a daily basis. Controls were sacrificed at the time therapy was begun in animals receiving antimicrobial agents. Sacrifice was followed by the determination of bacterial counts in vegetations and tissues (see below). For all comparisons, significant reductions were noted for animals receiving either drug (P < 0.0001 versus control). There were no differences between drug-treated animals. The same was true for the frequency at which both drugs produced culture-negative vegetations or tissues (P < 0.001 versus control).
Serum samples for the measurement No differences were found in the intensity of pretreatment bacteremia (mean ± standard deviation log1o CFU per milliliter) for animals receiving vancomycin (3.14 ± 0.51) or fleroxacin (2.78 ± 0.78) and sacrificed after 4 days of therapy or for controls sacrificed 18 h after bacterial challenge (3.09 ± 0.81). Peak and trough concentrations of vancomycin in serum were 29.70 ± 10.58 and 4.64 + 3.38 ,ug/ml, respectively (mean ± standard deviation). For fleroxacin, the corresponding values were 14.92 ± 4.37 and 1.33 ± 0.84 ,ug/ml. Geometric mean peak SITs and SBTs for animals receiving vancomycin were 1:30 and 1:15, respectively, and for those receiving fleroxacin, they were 1:22 and 1:8. The SITs for the two groups were not statistically different, but the SBTs were significantly higher for animals receiving vancomycin (P < 0.01).
There were no differences in the frequency of blood culture sterilization after 2 or 4 days of therapy. For animals that received vancomycin, 15 of 16 had sterile cultures after 2 and 4 days, while all 15 animals that received fleroxacin had sterile cultures on both days.
Quantitative bacterial counts found in vegetations and tissues are shown in Table 1 . The two drugs were equally effective in reducing these counts, and they produced equal proportions of culture-negative vegetations and tissues.
Cure of MRSA 494 endocarditis. Animals monitored for 7 days posttherapy had similar degrees of pretreatment bacteremia (vancomycin, 2.95 ± 0.95 [n = 9]; fleroxacin, 2.73 + 0.73 [n = 10]). Mean drug levels in serum, SITs, and SBTs were similar to those found in animals sacrificed following 4 days of therapy. There were no differences in the frequency of blood culture sterilization during or posttherapy.
Eight of nine vancomycin-treated and eight of ten fleroxacin-treated animals had sterile vegetations and tissues 7 days posttherapy and were considered cured of endocarditis. This difference was not significant. (3, 6, 13) . We have shown the same to be true for fleroxacin, a new trifluorinated quinolone. The drug cleared bacteremia, reduced bacterial counts in vegetations and tissues, and cured endocarditis with an efficacy equal to that of vancomycin. However, resistance to the drug at fivefold the MIC for the test strain was seen in a small proportion of organisms recovered from two animals. Serum fleroxacin concentrations in these animals were somewhat low, with peaks and troughs being nearly 50% below mean levels. It is possible that these low concentrations favored the development of resistance. Maintenance of higher levels in serum, nearer the mean peak and trough we achieved, may help to prevent this problem.
A difference was observed in plasma clearance of fleroxacin in well animals when the 17.5-mg/kg dose was compared with the 35-mg/kg dose. This was probably due to saturation of elimination pathways by the higher dose, resulting in diminished clearance. This hypothesis is supported by our finding of no differences in pharmacokinetic parameters other than clearance for the two dosing regimens. Such phenomena become important if they are not compensated for by adjustments in dosing interval or dose size, because the outcome of experimental infection could be affected.
Animals receiving vancomycin had significantly higher peak SBTs than those found in fleroxacin-treated animals. This difference did not result in an improved microbiologic outcome for those receiving vancomycin. We have found this to be true for ciprofloxacin in our previous studies with this animal model (6, 7) .
In conclusion, we have found fleroxacin to be equivalent to vancomycin in this model of a serious methicillin-resistant S. aureus infection. This drug may serve as an alternative to vancomycin in humans with similar infections, but modest resistance to the drug may develop during therapy.
